Morgan Stanley analyst Patrick Wood raised the firm’s price target on Edwards Lifesciences to $103 from $95 and keeps an Overweight rating on the shares. The firm’s new work and channel checks on Transcatheter Mitral & Tricuspid Therapies, or TMTT, suggests “sizeable upside risk to consensus through 2028+,” says the analyst, who is raising the firm’s out-year TMTT estimates by about 2%. In addition, trial readouts, indication expansions, and product launches add “spice to the story,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target raised to $100 from $93 at Oppenheimer
- Early notable gainers among liquid option names on March 14th
- Micron upgraded, Foot Locker downgraded: Wall Street’s top analyst calls
- Edwards Lifesciences upgraded to Buy at BofA after ‘bullish’ management meetings
- Edwards Lifesciences upgraded to Buy from Neutral at BofA